Tue, Mar 19, 2024
A A A
Welcome Guest
Free Trial RSS pod
Get FREE trial access to our award winning publications
Industry Updates

NEXTHERA adds former Citadel Portfolio Manager, Rael Mazansky

Thursday, March 30, 2017
Opalesque Industry Update - NEXTHERA Capital, a hedge fund manager concentrating in global therapeutics, announced the addition of Rael Mazansky M.D. to serve as Director of Research.

Working with NEXTHERA's co-Founder and CIO, Ori Hershkovitz, Mazansky will help drive NEXTHERA's investment strategy of seeking high risk-adjusted returns from the healthcare and therapeutics sectors.

NEXTHERA is a NY based fundamental long/short equity fund concentrating in global therapeutics (large cap pharmaceuticals, specialty pharmaceuticals/generics, and biotech). The firm was founded by Ori Hershkovitz, formerly head of pharmaceutical research at Sphera Funds Management, Israel's largest hedge fund, and is a top authority on Teva (in and out of Israel), alongside Daniel Malek, who was previously allocating capital to external managers at EJS Investment S.A.

"We are excited to hire an individual with a long and impressive history in healthcare investing. Rael will strengthen our team as we continue to develop the best human capital to produce innovative research and guidance for the portfolio," said Daniel Malek, co-Founder and CEO. "Rael's experience and perspective will help NEXTHERA attempt to capitalize on dynamic opportunities in this often misunderstood and complex area."

Mazansky joins NEXTHERA after being a healthcare portfolio manager at Surveyor Capital (Citadel), and previously holding senior biotech analyst roles at Perceptive Advisors and Ridgeback Capital.

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Previous Opalesque Exclusives                                  
Previous Other Voices                                               
Access Alternative Market Briefing

 



  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. KKR raises $6.4bn for the largest pan-Asia infrastructure fund[more]

    Laxman Pai, Opalesque Asia: The New York-based global investment firm KKR has raised a record $6.4bn for its second Asia-focused infrastructure fund, underlining investors' continued appetite for private markets. According to a media release from the alternative assets manager, the figure top

  2. Bucking the trend, top hedge fund makes plans for a second SPAC[more]

    From Institutional Investor: SPACs aren't dead. At least not to the folks at Cormorant Asset Management. The life sciences firm, whose hedge fund topped its peers in 2023, is confident it will match the success of its first blank-check company. Last week, the life sciences and biopharma speciali

  3. Benefit Street Partners closes fifth fund on $4.7 billion[more]

    Bailey McCann, Opalesque New York: Benefit Street Partners has closed its fifth flagship direct lending vehicle, BSP Debt Fund V, with $4.7 billion of investable capital across the strategy. Benefit Street invests primarily in privately originated, floating rate, senior secured loans. The fun

  4. 4 hedge fund themes that are working in 2024[more]

    From The Street: A poor earnings report from Tesla (TSLA) has not hurt the indexes on Thursday. The decline in Tesla stock, which is losing its position in the Magnificent Seven pantheon, is more than offset by strong earnings from IBM (IBM) and ServiceNow (NOW) . In addition, the much higher-t

  5. Opalesque Exclusive: A global macro fund eyes opportunities in bonds[more]

    Bailey McCann, Opalesque New York for New Managers: Munich-based ThirdYear Capital rebounded in 2023, following a tough year for global macro. The firm's flagship ART Global Macro strategy finished the year up 1